Indeed, several promising DYRK1A inhibitor drugs are currently in development for treatment of neurodegeneration, diabetes, and cancer (Pallavicini et al., 2019; Scavuzzo and Borowiak, 2020; Kumar et al., 2021; Liu T. et al., 2022; Guo et al., 2022; de Souza et al., 2023). Here, DYRK1A is linked to cancer.